[1]地里呼玛尔·吐鲁洪,曾慧娟综述,王少华审校.m6A甲基化在肿瘤中的作用研究进展[J].医学研究与战创伤救治(原医学研究生学报),2019,21(4):402-407.[doi:10.3969/j.issn.1672-271X.2019.04.015]
　Dilihumaer Tuluhong,ZENG Hui-juan reviewing,WANG Shao-hua checking.The role and mechanism of N6-methyladenosine (m6A) modification in cancer progression[J].JOURNAL OF MEDICALRESEARCH —COMBAT TRAUMA CARE,2019,21(4):402-407.[doi:10.3969/j.issn.1672-271X.2019.04.015]

点击复制

m6A甲基化在肿瘤中的作用研究进展()

分享到62.8K

参考文献/References:

1 SiegelRL, MillerKD, JemalA. Cancer statistics, 2019[J]. CA Cancer J Clin, 2019, 69(1): 7-34.
2 WeiCM, GershowitzA, MossB. Methylated nucleotides block 5' terminus of HeLa cell messenger RNA[J]. Cell, 1975,4(4):379-386.
3 DominissiniD, Moshitch-MoshkovitzS, SchwartzS, et al. Topology of the human and mouse m6A RNA methylomes revealed by m6A-seq[J]. Nature, 2012,485(7397):201-206.
4 LiuZX, LiLM, SunHL, et al. Link Between m6A Modification and Cancers[J]. Front Bioeng Biotechnol, 2018,6:89.
5 MeyerKD, SaletoreY, ZumboP, et al. Comprehensive analysis of mRNA methylation reveals enrichment in 3' UTRs and near stop codons[J]. Cell, 2012,149(7):1635-1646.
6 王天工,叶孟.m~6A甲基化与肿瘤研究进展[J].遗传,2018,40(12):1055-1065.
7 FuY, DominissiniD, RechaviG, et al. Gene expression regulation mediated through reversible m(6)A RNA methylation[J]. Nat Rev Genet, 2014,15(5):293-306.
8 CuiQ, ShiH, YeP, et al. m(6)A RNA Methylation Regulates the Self-Renewal and Tumorigenesis of Glioblastoma Stem Cells[J]. Cell Rep, 2017,18(11):2622-2634.
9 HuangY, YanJ, LiQ, et al. Meclofenamic acid selectively inhibits FTO demethylation of m6A over ALKBH5[J]. Nucleic Acids Res, 2015,43(1):373-384.
10 MeyerKD, JaffreySR. Rethinking m(6)A Readers, Writers, and Erasers[J]. Annu Rev Cell Dev Biol, 2017,33:319-342.
11 BujnickiJM, FederM, RadlinskaM, et al. Structure prediction and phylogenetic analysis of a functionally diverse family of proteins homologous to the MT-A70 subunit of the human mRNA:m(6)A methyltransferase[J]. J Mol Evol, 2002,55(4):431-444.
12 BarbieriI, TzelepisK, PandolfiniL, et al. Promoter-bound METTL3 maintains myeloid leukaemia by m(6)A-dependent translation control[J]. Nature, 2017,552(7683):126-131.
13 VuLP, PickeringBF, ChengY, et al. The N(6)-methyladenosine (m(6)A)-forming enzyme METTL3 controls myeloid differentiation of normal hematopoietic and leukemia cells[J]. Nat Med, 2017,23(11):1369-1376.
14 ZhangC, ZhiWI, LuH, et al. Hypoxia-inducible factors regulate pluripotency factor expression by ZNF217- and ALKBH5-mediated modulation of RNA methylation in breast cancer cells[J]. Oncotarget,2016,7(40):64527-64542.
15 CaiX, WangX, CaoC, et al. HBXIP-elevated methyltransferase METTL3 promotes the progression of breast cancer via inhibiting tumor suppressor let-7g[J]. Cancer Lett, 2018,415:11-19.
16 ChenM, WeiL, LawCT, et al. RNA N6-methyladenosine methyltransferase-like 3 promotes liver cancer progression through YTHDF2-dependent posttranscriptional silencing of SOCS2[J]. Hepatology, 2018,67(6):2254-2270.
17 TaketoK, KonnoM, AsaiA, et al. The epitranscriptome m6A writer METTL3 promotes chemo- and radioresistance in pancreatic cancer cells[J]. Int J Oncol, 2018,52(2):621-629.
18 LiX, TangJ, HuangW, et al. The M6A methyltransferase METTL3: acting as a tumor suppressor in renal cell carcinoma[J]. Oncotarget, 2017,8(56):96103-96116.
19 LiuJ, YueY, HanD, et al. A METTL3-METTL14 complex mediates mammalian nuclear RNA N6-adenosine methylation[J]. Nat Chem Biol, 2014,10(2):93-95.
20 WangX, HuangJ, ZouT, et al. Human m(6)A writers: Two subunits, 2 roles[J]. RNA Biol, 2017,14(3):300-304.
21 WengH, HuangH, WuH, et al. METTL14 Inhibits Hematopoietic Stem/Progenitor Differentiation and Promotes Leukemogenesis via mRNA m(6)A Modification[J]. Cell Stem Cell, 2018,22(2):191-205.
22 MaJZ, YangF, ZhouCC, et al. METTL14 suppresses the metastatic potential of hepatocellular carcinoma by modulating N(6) -methyladenosine-dependent primary MicroRNA processing[J]. Hepatology, 2017,65(2):529-543.
23 Pendleton KE, ChenB, LiuK, et al. The U6 snRNA m(6)A Methyltransferase METTL16 Regulates SAM Synthetase Intron Retention[J]. Cell, 2017,169(5):824-835.
24 WardaAS, KretschmerJ, HackertP, et al. Human METTL16 is a N(6)-methyladenosine (m(6)A) methyltransferase that targets pre-mRNAs and various non-coding RNAs[J]. EMBO Rep, 2017,18(11):2004-2014.
25 ShimaH, MatsumotoM, IshigamiY, et al. S-Adenosylmethionine Synthesis Is Regulated by Selective N(6)-Adenosine Methylation and mRNA Degradation Involving METTL16 and YTHDC1[J]. Cell Rep, 2017,21(12):3354-3363.
26 SchwartzS, MumbachMR, JovanovicM, et al. Perturbation of m6A writers reveals two distinct classes of mRNA methylation at internal and 5' sites[J]. Cell Rep, 2014,8(1):284-296.
27 PingXL, SunBF, WangL, et al. Mammalian WTAP is a regulatory subunit of the RNA N6-methyladenosine methyltransferase[J]. Cell Res, 2014,24(2):177-189.
28 SorciM, IannielloZ, CrucianiS, et al. METTL3 regulates WTAP protein homeostasis[J]. Cell Death Dis, 2018,9(8):796.
29 XiZ, XueY, ZhengJ, et al. WTAP Expression Predicts Poor Prognosis in Malignant Glioma Patients[J]. J Mol Neurosci, 2016,60(2):131-136.
30 LiBQ, HuangS, ShaoQQ, et al. WT1-associated protein is a novel prognostic factor in pancreatic ductal adenocarcinoma[J]. Oncol Lett, 2017,13(4):2531-2538.
31 TangJ, WangF, ChengG, et al. Wilms' tumor 1-associating protein promotes renal cell carcinoma proliferation by regulating CDK2 mRNA stability[J]. J Exp Clin Cancer Res, 2018,37(1):40.
32 GerkenT, GirardCA, TungYC, et al. The obesity-associated FTO gene encodes a 2-oxoglutarate-dependent nucleic acid demethylase[J]. Science, 2007,318(5855):1469-1472.
33 JiaG, FuY, ZhaoX, et al. N6-methyladenosine in nuclear RNA is a major substrate of the obesity-associated FTO[J]. Nat Chem Biol, 2011,7(12):885-887.
34 ZhaoX, YangY, SunBF, et al. FTO-dependent demethylation of N6-methyladenosine regulates mRNA splicing and is required for adipogenesis[J]. Cell Res, 2014,24(12):1403-1419.
35 JiaG, FuY, ZhaoX, et al. N6-methyladenosine in nuclear RNA is a major substrate of the obesity-associated FTO[J]. Nat Chem Biol, 2011,7(12):885-887.
36 TanA, DangY, ChenG, et al. Overexpression of the fat mass and obesity associated gene (FTO) in breast cancer and its clinical implications[J]. Int J Clin Exp Pathol, 2015,8(10):13405-13410.
37 SigurdsonAJ, BrennerAV, RoachJA, et al. Selected single-nucleotide polymorphisms in FOXE1, SERPINA5, FTO, EVPL, TICAM1 and SCARB1 are associated with papillary and follicular thyroid cancer risk: replication study in a German population[J]. Carcinogenesis, 2016,37(7):677-684.
38 LiZ, WengH, SuR, et al. FTO Plays an Oncogenic Role in Acute Myeloid Leukemia as a N(6)-Methyladenosine RNA Demethylase[J]. Cancer Cell, 2017,31(1):127-141.
39 ZhouS, BaiZ L, XiaD, et al. FTO regulates the chemo-radiotherapy resistance of cervical squamous cell carcinoma (CSCC) by targeting beta-catenin through mRNA demethylation[J]. Mol Carcinog, 2018,57(5):590-597.
40 MauerJ, LuoX, BlanjoieA, et al. Reversible methylation of m(6)Am in the 5' cap controls mRNA stability[J]. Nature, 2017,541(7637):371-375.
41 SuR, DongL, LiC, et al. R-2HG Exhibits Anti-tumor Activity by Targeting FTO/m(6)A/MYC/CEBPA Signaling[J]. Cell, 2018,172(1-2):90-105.
42 TongJ, FlavellRA, LiHB. RNA m(6)A modification and its function in diseases[J]. Front Med, 2018,12(4):481-489.
43 ZhangC, SamantaD, LuH, et al. Hypoxia induces the breast cancer stem cell phenotype by HIF-dependent and ALKBH5-mediated m(6)A-demethylation of NANOG mRNA[J]. Proc Natl Acad Sci USA, 2016,113(14):E2047-E2056.
44 ZhangS, ZhaoBS, ZhouA, et al. m(6)A Demethylase ALKBH5 Maintains Tumorigenicity of Glioblastoma Stem-like Cells by Sustaining FOXM1 Expression and Cell Proliferation Program[J]. Cancer Cell, 2017,31(4):591-606.
45 HeY, HuH, WangY, et al. ALKBH5 Inhibits Pancreatic Cancer Motility by Decreasing Long Non-Coding RNA KCNK15-AS1 Methylation[J]. Cell Physiol Biochem, 2018,48(2):838-846.
46 WangX, LuZ, GomezA, et al. N6-methyladenosine-dependent regulation of messenger RNA stability[J]. Nature, 2014,505(7481):117-120.
47 XiaoW, AdhikariS, DahalU, et al. Nuclear m(6)A Reader YTHDC1 Regulates mRNA Splicing[J]. Mol Cell, 2016,61(4):507-519.
48 ZhaoX, ChenY, MaoQ, et al. Overexpression of YTHDF1 is associated with poor prognosis in patients with hepatocellular carcinoma[J]. Cancer Biomark, 2018,21(4):859-868.
49 LiJ, MengS, XuM, et al. Downregulation of N(6)-methyladenosine binding YTHDF2 protein mediated by miR-493-3p suppresses prostate cancer by elevating N(6)-methyladenosine levels[J]. Oncotarget, 2018,9(3):3752-3764.
50 封冰,陈龙邦.微小RNA与表观遗传调控:肿瘤治疗新策略[J]. 医学研究生学报, 2011, 24(1): 92-95.
51 LiA, ChenYS, PingXL, et al. Cytoplasmic m(6)A reader YTHDF3 promotes mRNA translation[J]. Cell Res, 2017,27(3):444-447.
52 韦秀望,易晓明,唐朝朋,等.肾细胞癌组织中的组蛋白甲基化酶表达及其临床意义[J].医学研究生学报, 2015, 28(10): 1048-1052.
53 YinY, LongJ, SunY, et al. The function and clinical significance of eIF3 in cancer[J]. Gene, 2018,673:130-133.
54 LiZ, LinS, JiangT, et al. Overexpression of eIF3e is correlated with colon tumor development and poor prognosis[J]. Int J Clin Exp Pathol, 2014,7(10):6462-6474.
55 ChoeJ, LinS, ZhangW, et al. mRNA circularization by METTL3-eIF3h enhances translation and promotes oncogenesis[J]. Nature, 2018,561(7724):556-560.
56 段松.前列腺癌组织中Skp2的表达及其与前列腺癌术后复发的关系[J].东南国防医药,2016,18(1):47-50.
57 黄楚恒,李天然,黄晓斌,等.转移相关基因干扰对肝癌转移潜能的影响[J].东南国防医药,2016,18(3):225-229,236.

相似文献/References: